Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_provenance.
- NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_assertion description "[This phase II study assesses the impact of second-line weekly irinotecan (CPT-11)/docetaxel in non-small cell lung cancer (NSCLC) patients, and gauges the uridine diphosphate glucuronosyl transferase (UGT1A1) polymorphism influence in toxicity and antitumor activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_provenance.
- NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_assertion evidence source_evidence_literature NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_provenance.
- NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_assertion SIO_000772 14586211 NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_provenance.
- NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_assertion wasDerivedFrom befree-2016 NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_provenance.
- NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_assertion wasGeneratedBy ECO_0000203 NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_provenance.
- befree-2016 importedOn "2016-02-19" NP418726.RAASKb_L_LkoQWvAD5m9qJLnkZ-1WAZapf_UCInAY6ZeA130_provenance.